3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
64
Neoplasms
8
Sarcoma
6
Ovarian Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Sarcoma, Ewing
4
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Glioma
4
Carcinoma, Non-Small-Cell Lung
4
Rhabdomyosarcoma
3
Rhabdoid Tumor
3
Prostatic Neoplasms
3
Osteosarcoma
3
Neuroblastoma
3
Melanoma
3
Medulloblastoma
3
Lymphoma
3
Liposarcoma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lung Neoplasms
2
Kidney Neoplasms
2
Interventions
Hydroxychloroquine
4
Standard of Care
2
Sodium Chloride
2
COH04S1 COVID-19 vaccine
2
BNT162 Vaccine
2
Azithromycin
2
tocilizumab
1
palbociclib
1
ogalvibart
1
monalizumab
1
crexavibart
1
cilgavimab and tixagevimab drug combination
1
avdoralimab
1
XAV-19
1
Specimen Handling
1
Radiotherapy
1
Medical Marijuana
1
Losartan
1
Janus Kinase Inhibitors
1
Ivermectin
1
Interleukin-7
1
HuMax-IL8
1
Gelsolin
1
CVnCoV COVID-19 vaccine
1
COVID-19 Vaccines
1
2019-nCoV Vaccine mRNA-1273
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
COVID-19
×
palbociclib
×
Clear all
NCT05371275
2022-11-07
CDK6COV
biotx.ai GmbH
Phase 2
Withdrawn